Climb Bio, Inc. — Director's Dealing 2021

Aug 16, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Eliem Therapeutics, Inc. (ELYM)
CIK: 0001768446
Period of Report: 2021-08-12

Reporting Person: RA CAPITAL MANAGEMENT, L.P. (Director, 10% Owner)
Reporting Person: RA Capital Healthcare Fund LP (Director, 10% Owner)
Reporting Person: RA Capital Nexus Fund, L.P. (Director, 10% Owner)
Reporting Person: RA Capital Nexus Fund II, L.P. (Director, 10% Owner)
Reporting Person: Kolchinsky Peter (Director, 10% Owner)
Reporting Person: Shah Rajeev M. (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-12	Common Stock	C	4727585	—	Acquired	7594804	Indirect
2021-08-12	Common Stock	P	3004782	$12.50	Acquired	10599586	Indirect
2021-08-12	Common Stock	C	1226497	—	Acquired	1226497	Indirect
2021-08-12	Common Stock	C	288461	—	Acquired	288461	Indirect
2021-08-12	Common Stock	P	195218	$12.50	Acquired	483679	Indirect
2021-08-12	Common Stock	C	624974	—	Acquired	841087	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-08-12	Series A Preferred Stock	$	C	2639507	Disposed		Common Stock (2639507)	Indirect
2021-08-12	Series A-1 Preferred Stock	$	C	1415002	Disposed		Common Stock (1415002)	Indirect
2021-08-12	Series B Preferred Stock	$	C	673076	Disposed		Common Stock (673076)	Indirect
2021-08-12	Series A Preferred Stock	$	C	708333	Disposed		Common Stock (708333)	Indirect
2021-08-12	Series A-1 Preferred Stock	$	C	518164	Disposed		Common Stock (518164)	Indirect
2021-08-12	Series B Preferred Stock	$	C	288461	Disposed		Common Stock (288461)	Indirect
2021-08-12	Series A Preferred Stock	$	C	485493	Disposed		Common Stock (485493)	Indirect
2021-08-12	Series A-1 Preferred Stock	$	C	139481	Disposed		Common Stock (139481)	Indirect

Footnotes

F1: On August 12, 2021, each share of Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into one share of Common Stock of the Issuer without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

F2: These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F3: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

F4: These securities are held directly by the Nexus Fund.

F5: These securities are held directly by the Nexus Fund II.

F6: These securities are held directly by the Account.